Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
8120 results about "Target gene" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
"Target Gene" often just means "Gene Of Interest", or the particular gene being studied or manipulated in an experiment.
Genetic constructs for delaying or repressing the expression of a target gene
The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.
Owner:COMMONWEALTH SCI & IND RES ORG
Use of chimeric nucleases to stimulate gene targeting
ActiveUS20050026157A1Ameliorate genetic disorderIncrease productionAntibacterial agentsFusion with DNA-binding domainGene targetsGenetic Change
Gene targeting is a technique to introduce genetic change into one or more specific locations in the genome of a cell. For example, gene targeting can introduce genetic change by modifying, repairing, attenuating or inactivating a target gene or other chromosomal DNA. In one aspect, this disclosure relates to methods and compositions for gene targeting with high efficiency in a cell. This disclosure also relates to methods of treating or preventing a genetic disease in an individual in need thereof. Further disclosed are chimeric nucleases and vectors encoding chimeric nucleases.
Owner:CALIFORNIA INST OF TECH
Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
InactiveUS20080113351A1High RNA interference effectLittle riskOrganic active ingredientsNervous disorderBase JNucleotide
The present invention provides a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene. A sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene for RNA interference and, based on the search results, a polynucleotide capable of causing RNAi is designed, synthesized, etc.:(a) The 3′ end base is adenine, thymine, or uracil,(b) The 5′ end base is guanine or cytosine,(c) A 7-base sequence from the 3′ end is rich in one or more types of bases selected from the group consisting of adenine, thymine, and uracil, and(d) The number of bases is within a range that allows RNA interference to occur without causing cytotoxicity.
Owner:ALPHAGEN
Modified siRNA molecules and uses thereof
ActiveUS20070135372A1Decrease immunostimulatory propertyImmunostimulatory activity of siRNA can be abolishedOrganic active ingredientsSugar derivativesLipid formationLipid particle
The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and / or modifying an siRNA having immunostimulatory properties are also provided.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Modular dna-binding domains and methods of use
InactiveUS20110239315A1Enabling targeted DNA modificationFungiBacteriaDNA-binding domainDna targeting
The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
Owner:BONAS ULLA +2
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Owner:CITY OF HOPE +1
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
InactiveUS20070265220A1Improve stabilityConvenience to mergeSenses disorderAntipyreticDouble strandOligonucleotide
The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Owner:CITY OF HOPE +1
Methods for detection of genetic disorders
InactiveUS7727720B2Maximize efficiencyIncrease delaySugar derivativesMicrobiological testing/measurementGeneticsAllele
The invention provides a method useful for detection of genetic disorders. The method comprises determining the sequence of alleles of a locus of interest, and quantitating a ratio for the alleles at the locus of interest, wherein the ratio indicates the presence or absence of a chromosomal abnormality. The present invention also provides a non-invasive method for the detection of chromosomal abnormalities in a fetus. The invention is especially useful as a non-invasive method for determining the sequence of fetal DNA. The invention further provides methods of isolation of free DNA from a sample.
Owner:RAVGEN INC
Methods for detection of genetic disorders
InactiveUS7442506B2Maximize efficiencyIncrease delaySugar derivativesMicrobiological testing/measurementGeneticsAllele
The invention provides a method useful for detection of genetic disorders. The method comprises determining the sequence of alleles of a locus of interest, and quantitating a ratio for the alleles at the locus of interest, wherein the ratio indicates the presence or absence of a chromosomal abnormality. The present invention also provides a non-invasive method for the detection of chromosomal abnormalities in a fetus. The invention is especially useful as a non-invasive method for determining the sequence of fetal DNA. The invention further provides methods of isolation of free DNA from a sample.
Owner:RAVGEN INC
Methods for detection of genetic disorders
InactiveUS20070178478A1Minimize disruptionMaximize efficiencyMicrobiological testing/measurementFermentationGeneticsAllele
The invention provides a method useful for detection of genetic disorders. The method comprises determining the sequence of alleles of a locus of interest, and quantitating a ratio for the alleles at the locus of interest, wherein the ratio indicates the presence or absence of a chromosomal abnormality. The present invention also provides a non-invasive method for the detection of chromosomal abnormalities in a fetus. The invention is especially useful as a non-invasive method for determining the sequence of fetal DNA. The invention further provides methods of isolation of free DNA from a sample.
Owner:RAVGEN INC
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
Owner:CITY OF HOPE +1
Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism
ActiveUS20070275465A1Improve stabilityGreat to enzymatic digestionSugar derivativesMicrobiological testing/measurementSingle strandDouble strand
The invention concerns a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, whereby the sequences of the single strands of the dsRNA are selected in such a way that on both ends of the dsRNA the last complementary nucleotide pair is a G-C, or at least two of the last four complementary nucleotide pairs are G-C pairs; whereby the dsRNA exhibits a single-stranded overhang consisting of 1 to 4 unpaired nucleotides at the first end, and no overhang at the second end; whereby the unpaired nucleotide of the single-stranded overhang that is directly adjacent to the last complementary nucleotide pair contains a purine base.
Owner:ALNYLAM PHARM INC
Identification and use of target genes for control of plant parasitic nematodes
ActiveUS20070250947A1Raise the possibilityLevel confidenceBiocideOrganic active ingredientsNematodePlant cell
The invention relates to identifying and evaluating target coding sequences for control of plant parasitic nematodes by inhibiting one or more biological functions, and their use. The invention provides methods and compositions for identification of such sequences and for the control of a plant-parasitic nematode population. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the nematode, a reduction in disease may be obtained through suppression of nematode gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and the plant cells and plants obtained thereby.
Owner:MONSANTO TECH LLC
Methods for targeted genomic analysis
ActiveUS20140274731A1Sugar derivativesMicrobiological testing/measurementSpecific detectionGene expression profiling
The invention provides a method for genetic analysis in individuals that reveals both the genetic sequences and chromosomal copy number of targeted and specific genomic loci in a single assay. The present invention further provide methods for the sensitive and specific detection of target gene sequences and gene expression profiles.
Owner:RESOLUTION BIOSCI
2'-f modified RNA interference agents
InactiveUS20110269814A1Inhibit expressionSuppress gene expressionOrganic active ingredientsSugar derivativesNucleotideSense strand
This invention relates to a method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein the iRNA comprises at least one 2′-deoxy-2′-fluoro (2′-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand. The invention also relates to compositions comprising a single-stranded oligonucleotide that contains at least one 2′-deoxy-2′-fluoro (2′-F) nucleotide. siRNA molecule containing these oligonucleotides have decreased immunogenicity.
Owner:ALNYLAM PHARM INC
Wheat genome site-specific modification method
The invention discloses a wheat genome site-specific modification method which comprises the following steps: enabling wheat tissues to contain guide RNA (ribonucleic acid) and Cas9 nuclease; under the coaction of the guide RNA and Cas9 nuclease, cutting a double-chain target segment on the target gene; and by utilizing the DNA (deoxyribonucleic acid) restoration function of the wheat cells, finally implementing random insertion and / or random deletion on the target segment in the wheat target gene. The experiment proves that the method disclosed by the invention can successfully perform gene mutation on wheat.
Owner:SUZHOU QI BIODESIGN BIOTECHNOLOGY CO LTD
Synthetic genes and genetic constructs comprising same i
The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.
Owner:COMMONWEALTH SCI & IND RES ORG
Gene detection field-effect device and method of analyzing gene polymorphism therewith
ActiveUS7695907B2High degreeReduction of size and costBioreactor/fermenter combinationsBiological substance pretreatmentsNucleic Acid ProbesBiology
A gene detection field-effect device provided with an insulation film (2), a semiconductor substrate (3), and a reference electrode (4), includes: (a) the insulation film (2) including a nucleic acid probe (5) immobilized on one of the surfaces thereof and is in contact with a sample solution (6) containing at least one type of a target gene (601) for detection and analysis; (b) the semiconductor substrate (3) being installed so as to abut against the other surface of the insulation film (2); and (c) the reference electrode (4) being provided in the sample solution (6).
Owner:NAT INST FOR MATERIALS SCI
Compositions and methods for inhibiting expression of a target gene
ActiveUS7829693B2Inhibit expression of target geneOrganic active ingredientsNervous disorderDiseaseNucleotide
The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3′-end and a blunt 5′-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
Owner:ALNYLAM PHARM INC
Glycoconjugates of RNA Interference Agents
ActiveUS20090203135A1Inhibit expression of target geneInhibit expressionOrganic active ingredientsSugar derivativesGlycoconjugateCancer research
The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Owner:ALNYLAM PHARM INC
Method for constructing gene site-directed mutation
ActiveCN103388006AEfficient constructionRaise the ratioVector-based foreign material introductionForeign genetic material cellsMulti siteEmbryo
Owner:BIORAY LABORATORIES INC
Inhibitor nucleic acids
InactiveUS20050256071A1Low melting pointQuality improvementOrganic active ingredientsNervous disorderAptamerHalf-life
The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism. In particular, the RNAi constructs may include one or more modifications to improve serum stability, cellular uptake and / or to avoid non-specific effect. In certain embodiments, the RNAi constructs contain an aptamer portion. The aptamer may bind to human serum albumin to improve serum half life. The aptamer may also bind to a cell surface protein that improves uptake of the construct.
Owner:CALIFORNIA INST OF TECH
Synthetic genes and genetic constructs comprising same I
Owner:COMMONWEALTH SCI & IND RES ORG
Expression monitoring by hybridization to high density oligonucleotide arrays
InactiveUS6927032B2Reduce complexityReduce background signalBioreactor/fermenter combinationsBiological substance pretreatmentsHigh densityOligonucleotide
This invention provides methods of monitoring the expression levels of a multiplicity of genes. The methods involve hybridizing a nucleic acid sample to a high density array of oligonucleotide probes where the high density array contains oligonucleotide probes complementary to subsequences of target nucleic acids in the nucleic acid sample. In one embodiment, the method involves providing a pool of target nucleic acids comprising RNA transcripts of one or more target genes, or nucleic acids derived from the RNA transcripts, hybridizing said pool of nucleic acids to an array of oligonucleotide probes immobilized on surface, where the array comprising more than 100 different oligonucleotides and each different oligonucleotide is localized in a predetermined region of the surface, the density of the different oligonucleotides is greater than about 60 different oligonucleotides per 1 cm2, and the olignucleotide probes are complementary to the RNA transcripts or nucleic acids derived from the RNA transcripts; and quantifying the hybridized nucleic acids in the array.
Owner:AFFYMETRIX INC
Antisense oligonucleotides optimized for kidney targeting
ActiveUS20050113326A1Growth inhibitionPreventing delaying onsetSugar derivativesSpecial deliveryConnective tissue fiberCTGF
The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
Owner:IONIS PHARMA INC
Cancer screening method
InactiveUS20080311570A1Accurate screening resultEasy diagnosisMicrobiological testing/measurementFermentationScreening cancerScreening method
A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.
Owner:NAT DEFENSE MEDICAL CENT
Transgenic dunaliella salina as a bioreactor
Disclosed is a method for making a bioreactor comprising a foreign target gene, special selectable markers and Dunaliella Salina as host. It is prepared by the genetic transformation techniques that include introducing a foreign target gene into the cells of Dunaliella Salina and screening the transformed cells of Dunaliella Salina. The bioreactor of the present invention can be used as a safe and cheap production system for proteins of pharmaceutical interest including vaccines, especially oral products, in a large scale, because the cells of Dunaliella Salina are easy of genetic manipulation in preparation of the bioreactor, nontoxic and edible for humans and animals, and harmless to the environment.
Owner:XUE LEXUN +1
Control of gene expression
Owner:COMMONWEALTH SCI & IND RES ORG
Recombinant plant viral vectors
Disclosed are nucleic acid vectors which comprise: (a) a transfer nucleotide sequence comprising (i) a plant active promoter, operably linked to (ii) a recombinant tobacco rattle virus (TRV) cDNA (preferably derived from TRV RNA2) which includes at least cis acting elements permitting replication of the cDNA; a subgenomic promoter operably linked to a sequence encoding a TRV coat protein; and a heterologous nucleotide sequence which is foreign to the virus;(b) border sequences which permit the transfer of the transfer nucleotide sequence into a plant genome. Such vectors may be used as expression vectors or for achieving viral induced gene silencing (VIGS) of a target gene, wherein the heterologous nucleotide sequence is a targeting sequence which corresponding to that gene. Example vectors include pTV00 and vectors which are derived from PTV00 and have the characteristics thereof. Also disclosed are associated processes, methods, viruses or viral particle, kits, host cells and plant tissues.
Owner:PLANT BIOSCI LTD
MODIFIED siRNA MOLECULES AND USES THEREOF
ActiveUS20090270481A1Decrease immunostimulatory propertyImmunostimulatory activity of siRNA can be abolishedOrganic active ingredientsSugar derivativesLipid formationLipid particle
The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and / or modifying an siRNA having immunostimulatory properties are also provided.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com